| Ytd | -67.37% | |
| 1y | -46.32% |
| Open | 4.39 | Prev Close | 4.37 | Low | 4.15 | High | 4.51 | Mkt Cap | 28.64M |
| Vol | 138.55K | Avg Vol | 310.20K | EPS | 21.56 | P/E | 0.19 | Forward P/E | -0.52 |
| Beta | 0.69 | Short Ratio | 0.98 | Inst. Own | 11.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 5.61 | 200-d Avg | 9.60 | 1yr Est | 15.75 |
PSTV News
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Tr
Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial gui
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirm
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plu
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lo
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P